Targeting calciphylaxis: the emergence of vitamin K as a potential treatment

Clicks: 15
ID: 327062
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #183 of 228 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 228 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Calciphylaxis, or calcific uraemic arteriolopathy (CUA), is a rare, life-threatening vascular disorder predominantly affecting patients with advanced chronic kidney disease (CKD), especially those on dialysis. It is characterized by arteriolar calcification, thrombosis, and painful ischemic skin lesions that frequently ulcerate, contributing to high morbidity and mortality. Calciphylaxis arises from medial arterial calcification, endothelial injury, and a pro-inflammatory, pro-thrombotic milieu. Disruption of vitamin K–dependent pathways, particularly impaired γ-carboxylation of matrix Gla protein (MGP), a potent inhibitor of vascular calcification, has emerged as a key mechanistic contributor. Functional vitamin K deficiency is common in CKD and is exacerbated by vitamin K antagonists such as warfarin, which markedly increase calciphylaxis risk. Observational studies show elevated levels of inactive MGP and other undercarboxylated Gla proteins in affected patients, linking vitamin K insufficiency to disease pathogenesis. Case reports and preliminary interventional studies suggest that vitamin K supplementation could restore MGP activity, reduce vascular calcification, and support wound healing, robust randomized controlled trial data are lacking. Ongoing trials, including the BEAT-Calci adaptive platform, aim to clarify the efficacy, optimal dosing, and safety of vitamin K as a targeted therapeutic strategy. Precision medicine approaches using vitamin K biomarkers and individualized anticoagulation may further improve outcomes. In conclusion, vitamin K–dependent pathways represent a promising mechanistic and potentially modifiable target in calciphylaxis. High-quality clinical trials are urgently needed to validate supplementation strategies and develop evidence-based, individualized management protocols for this severe condition.
Reference Key
openalex_W7204950471 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Maria Fusaro, Smeeta Sinha, Antonio Bellasi, Markus Ketteler, Carlo Alfieri, Martin H. de Borst, Ditte Hansen, Pietro Manuel Ferraro, Juan Miguel Díaz‐Tocados, Mathias Haarhaus, Mehmet Kanbay, Maurizio Gallieni, Paolo Simioni, Sandro Giannini, Sharon Huish, Althea Cossettini
Are you one of these authors? Claim your profile
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag286
URL
https://doi.org/10.1093/ckj/sfag286
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.